Chocoladefabriken Lindt & Spruengli AG Part. Cert. (0QP1)
London Exchange · UK · prices in GBP · close of 23 Oct 2026
Key indicators
| Last close | GBP 8,490.00 |
|---|---|
| 52-week range | 7,420.00 – 13,460.00 |
| Return, 1 month / 3 months | −1.7% / −6.8% |
| Return, 1 year / 3 years | −36.0% / −13.3% |
| Trend | Below its 200-day average |
| RSI (14) | 58 |
| Volatility (1 year) | 24.7% |
| Worst drawdown (1 year) | -44.1% |
| Average daily value traded | 6.67M GBP |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Chocoladefabriken Lindt & Spruengli is a Swiss chocolate maker based in Kilchberg, near Zurich. It produces chocolate bars, pralines and truffles, including its Lindor range and its foil-wrapped seasonal bunny, and it also runs its own chocolate shops alongside sales through retailers and distributors. Its products reach customers in many countries, and the company operates production sites in Switzerland and elsewhere in Europe and North America.
The shares are listed on the London Exchange in UK under the code 0QP1, and the price on this page is in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Chocoladefabriken Lindt & Spruengli AG Part. Cert. (0QP1) trades on the London Exchange in UK. It last closed at GBP 8,490.00 on 23 October 2026.
Its price-based Market X-Ray is 38 out of 100 (a weak price profile), ranking 2,730 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 36.0% and over the last three months it fell 6.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 20 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -13.7% | ||
| From 52-week high | -36.0% | ||
| Momentum | 24 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -6.8% | ||
| 6-month return | -13.1% | ||
| 12-month return, skipping the last month | -34.9% | ||
| Stability (higher is calmer) | 51 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 24.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -44.1% | ||
| Liquidity | 70 · Strong | Trades actively. | |
| Average daily value traded | 6.67M GBP | ||
| Zero-volume days | 6.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +0.7% |
|---|---|
| 1 month | −1.7% |
| 3 months | −6.8% |
| 6 months | −13.1% |
| 1 year | −36.0% |
| 3 years | −13.3% |
| 5 years | −21.3% |
Signals
| 50-day / 200-day average | 8,470.12 / 9,837.80 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 381.23 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 20 Apr 2026 | GBX 1.8000 |
| 22 Apr 2025 | GBX 1.5000 |
| 22 Apr 2024 | GBX 1.4000 |
| 24 Apr 2023 | GBX 1.3000 |
| 3 May 2022 | GBX 1.2000 |
| 6 May 2021 | GBX 0.3690 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.